Johnson & Johnson (JNJ) stock prices updated...
 

Johnson & Johnson stock price

Johnson & Johnson latest news:


  • 11/16/2017 14:02:13

    UPDATE 3-J&J wins California lawsuit claiming asbestos in talc caused cancer

    Nov 16 (Reuters) - A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

  • 11/16/2017 12:32:42

    UPDATE 2-J&J wins Calif. lawsuit claiming asbestos in talc caused cancer

    Nov 16 (Reuters) - A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

  • 11/16/2017 11:59:32

    UPDATE 1-J&J wins Calif. lawsuit claiming asbestos in talc caused cancer

    Nov 16 (Reuters) - A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

  • 11/16/2017 11:35:33

    J&J wins Calif. lawsuit claiming asbestos in talc caused cancer

    A California jury on Thursday ruled in favor of Johnson & Johnson (JNJ) in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder. The Los Angeles Superior Court jury's verdict came in the first trial centering on claims that J&J's talc products contained asbestos.

  • 11/16/2017 10:58:20

    Johnson & Johnson hit with $247 mln verdict in hip implant trial

    NEW YORK, Nov 16 (Reuters) - A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

  • 11/14/2017 14:34:02

    Achillion shares drop as J&J to sell large stake

    Achillion Pharmaceuticals Inc. shares fell in the extended session Tuesday after the drug developer reported promising early data on one of its kidney-disease treatments but said a large stakeholder was selling shares in a secondary offering. Achillion shares fell 9.2% to $3.35 after hours. Achillion said Johnson & Johnson Inc.'s venture capital arm, Johnson & Johnson Innovation-JJDC Inc., will sell 18.4 million shares of Achillion in a public offering and that Achillion would not receive proceeds. Achillion has 136.9 million shares outstanding. Separately, the company said early data from its mid-stage clinical trial for ACH-4471 showed the drug reduced protein in the urine by more than 50% in patients with C3 glomerulopathy, a rare disease where protein deposits build up in the kidneys.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/10/2017 07:58:15

    McDonald's stock is the biggest drag on the Dow for a second straight session

    The Dow Jones Industrial Average on Friday was being weighed by slumping shares of McDonald's Corp., for a second straight session. The fast-food chain's shares were, down 1.4%, or $2.35, cutting about 15 points from the price-weighted Dow . Shares of McDonald's fell 1.8%, or $3.10, on Thursday, serving as the biggest drag on the Dow, which closed off more than 100 points on the day. Shares o Johnson & Johnson and Boeing Co. also were contributed to the price-weighted blue-chip index's decline. A $1 swing in any one of the Dow's components equates to a move of 6.89 points. More broadly, the S&P 500 index was off 6 points, or 0.2%, at 2,578, while the Nasdaq Composite Index retreated 7 points, or 0.1%, at 6,742, in early trade. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/26/2017 01:39:40

    Pfizer sets date for auction of consumer healthcare unit: Reuters

    Pfizer Inc. will begin the auction process for its consumer healthcare unit in November, which it hopes will end in a $15 billion sale, Reuters reported late Wednesday, citing sources close to the matter. GlaxoSmithKline PLC. and Reckitt Benckiser are among those companies that have said they would consider bidding for the Pfizer unit. One of the sources told Reuters that initial discussions with Reckitt have already happened. Other possible bidders may include Procter & Gamble , Sanofi SA , Johnson & Johnson and Nestle [s: ch:nesn], sources said. The companies have been contacted for comment.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/20/2017 18:12:19

    California judge tosses $417 million talc cancer verdict against Johnson & Johnson

    (Reuters) - A California judge on Friday threw out a $417 million verdict against Johnson & Johnson in a lawsuit by a woman who claimed she developed ovarian cancer after using its talc-based products like Johnson's Baby Powder for feminine hygiene.

  • 10/20/2017 18:07:45

    California judge tosses $417 mln talc cancer verdict against J&J

    Oct 20 (Reuters) - A California judge on Friday threw out a $417 million verdict against Johnson & Johnson in a lawsuit by a woman who claimed she developed ovarian cancer after using its talc-based products like Johnson's Baby Powder for feminine hygiene.

  • 10/18/2017 09:40:30

    Analysts Piling On to Raise Johnson & Johnson Price Targets Higher and Higher


  • 10/17/2017 14:01:41

    UnitedHealth, Johnson & Johnson Lead Dow Higher Tuesday


  • 10/17/2017 13:50:13

    UPDATE 2-J&J wins reversal of $72 mln verdict over talc cancer risks

    Oct 17 (Reuters) - Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.

  • 10/17/2017 13:00:09

    New cancer drugs help Johnson & Johnson top profit estimates

    (Reuters) - Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year.

  • 10/17/2017 10:56:37

    J&J wins reversal of $72 million verdict over talc cancer risks

    Oct 17 (Reuters) - Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.

  • 10/17/2017 10:55:05

    Appeals court tosses $72 million award in talcum powder case

    A Missouri appeals court has thrown out a $72 million award to a woman who claimed talcum powder made by Johnson & Johnson contributed to her ovarian cancer.

  • 10/17/2017 10:53:57

    Appeals court tosses $72 million verdict in lawsuit alleging Johnson & Johnson talcum powder contributed to cancer

    Appeals court tosses $72 million verdict in lawsuit alleging Johnson & Johnson talcum powder contributed to cancer.

  • 10/17/2017 09:36:27

    Johnson & Johnson tops Street 3Q forecasts, hikes forecast

    Johnson & Johnson beats Wall Street expectations but net income drops 12 percent on higher costs

  • 10/13/2017 15:03:12

    J&J psoriasis drug gets expanded U.S. approval for teens

    Oct 13 (Reuters) - Johnson & Johnson said on Friday it has received an expanded U.S. approval for its blockbuster psoriasis drug Stelara to treat adolescent patients aged 12 and over with moderate to severe cases of the unsightly skin condition.

  • 10/11/2017 14:19:06

    Dow, S&P 500, Nasdaq notch all-time highs after Fed minutes

    U.S. stock benchmarks closed at records on Wednesday after minutes from the Federal Reserve's policy-setting gathering in September indicated a desire to increase rates one additional time despite stubbornly low inflation. Some Fed policy members expressed concerns about inflation running below its 2% annual target, while others worried that waiting for inflation to normalize policy could lead to an overheated market. The Dow Jones Industrial Average rose about 42.21 points, or 0.2%, at 22,872.89, supported by sharp climbs in the shares of components McDonald's Corp. and Johnson & Johnson . The S&P 500 index ended about 4.6 points, or 0.2%, at 2,555.24, with shares of retailing giants Target Corp. and Wal-Mart Stores Inc. leading gains in the broad-market index. Meanwhile, the technology-laden Nasdaq Composite Index climbed 16.30 points, or 0.3%, to 6,603.55. All three benchmarks ended at records. The account of the Fed's discussions during its September meeting suggests that the central bank would likely raise rates at a gradual pace. In other corporate news, shares of BlackRock Inc. rose after posting better-than-expected earnings, with a spate of earnings from financials set to be released early Thursday. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/11/2017 14:03:32

    Stock market notches trifecta of all-time highs as Fed minutes hint at gradual rate hikes

    U.S. stocks closed at all-time highs on Wednesday after minutes from the Federal Reserve's policy-setting gathering in September indicated a desire to increase rates one additional time despite stubbornly low inflation. Some Fed policy members expressed concerns about inflation running below its annual 2% target, while others worried that waiting for inflation to normalize policy could lead to an overheated market. The Dow Jones Industrial Average rose about 40 points, or 0.2%, at 22,8, supported by sharp climbs in the shares of components McDonald's Corp. and Johnson & Johnson . The S&P 500 index ended about 4.5 points, or 0.2%, at 2,555, with shares of retailing giants Target Corp. and Wal-Mart Stores Inc. leading gains in the broad-market index. Meanwhile, the technology-laden Nasdaq Composite Index climbed 16 points, or 0.3%, to a record 6,603. All three benchmarks ended at records. The account of the Fed's discussions during its September meeting suggests that the central bank would likely raise rates at a gradual pace. In other corporate news, shares of BlackRock Inc. rose after posting better-than-expected earnings, with a spate of earnings from financials set to be released early Thursday. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/11/2017 14:01:08

    Walmart, Johnson & Johnson Lift DJIA Wednesday


  • 09/28/2017 14:08:28

    Risk on All Sides as 4,800 Women Sue Over Johnson’s Baby Powder and Cancer

    Johnson & Johnson has been accused of causing thousands of cases of ovarian cancer by plaintiffs who are mostly taking the company to court individually, not as a team.

  • 09/20/2017 13:35:29

    Pfizer accuses Johnson & Johnson of 'anticompetitive practices' in lawsuit

    Pfizer filed a lawsuit against fellow pharmaceutical giant Johnson & Johnson over "anticompetitive practices" with the drug Remicade.        

  • 09/20/2017 13:24:42

    Pfizer files suit against J&J over Remicade contracts

    (Reuters) - Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson , saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

  • 09/06/2017 06:29:53

    Vertex Pharma surges 1% after news of new CFO

    Vertex Pharmaceuticals Inc. shares surged 1.2% in premarket trade Wednesday after the company announced that Tom Graney would be its new chief financial officer and senior vice president, starting September 13. Graney will report to Ian Smith, Vertex's chief operating officer and executive vice president, who has been Vertex's chief financial officer for 16 years. Graney most recently served as CFO and senior vice president of finance and corporate strategy at Ironwood Pharmaceuticals . Graney was in his Ironwood Pharma position for just over three years, according to his LinkedIn profile; he previously worked at Johnson & Johnson and its Ethicon and Janssen business units, among other places. Vertex shares have surged 24.6% to $159.07 over the last three months, compared with a 1.2% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/30/2017 13:58:01

    Travelers stock weighs on Dow industrials in late trade

    The Dow Jones Industrial Average on Wednesday was seeing modest gains capped in late-afternoon trade partly on the back of a decline in insurer Travelers Cos. Inc. in the wake of the Hurricane Harvey. The Dow briefly slipped into negative territory, with Travelers stock down 1% as the impact of a now-Tropical storm Harvey was being assessed in the Houston and Louisiana area. Some estimates peg losses in the Gulf Coast region at around $160 billion, which could hit insurance companies. Meanwhile, shares of Johnson & Johnson and UnitedHealth Group Inc. were also pressuring the blue-chip benchmark. Most recently, the Dow was up less than 0.1% at 21,885, while the S&P 500 index climbed 0.5%, and the Nasdaq Composite Index looked on track to post a more than 1% advance. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Johnson ControlsJCI | Jones EnergyJONE | Jones Lang LaSalle IncorporatedJLL | Journal Media GroupJMG | Joy Global Inc.JOY | JP Energy Partners LPJPEP | JPMorgan China Region FundJFC | Jumei International Holding LimitedJMEI | Juniper NetworksJNPR | Jupai Holdings LimitedJP |